Not Yet RecruitingNCT05891639
This study is looking at investigate the safety and efficacy of bipolarity treatments. Participants are followed over time so researchers can learn from clinical and follow-up information.
BipolarityOtherOver 18 Years
- Countries
- United States
- Sponsor
- Power Life Sciences Inc.
- Condition
- Bipolarity
Active Not RecruitingNCT06609902
This study is looking at whether Future Self-BD can help people with bipolarity or Tobacco Use Disorder. Participants take part in Future Self-BD and complete follow-up assessments.
BipolarityBehavioralOver 18 Years
- Countries
- United States
- Sponsor
- Massachusetts General Hospital
- Condition
- Bipolarity
RecruitingNCT06508450
This study is looking at whether Just Do You can help people with Psychosis, bipolarity, or depression. Participants take part in the program and complete follow-up questionnaires or assessments.
DepressionBehavioralFrom 18 Years to 34 Years
- Countries
- United States
- Sponsor
- New York University
- Condition
- Depression
RecruitingNCT05537376
This study is looking at whether a digital support tool can help people with psychosis, bipolarity, Suicidal Ideation, or Suicide, Attempted. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.
BipolarityBehavioralOver 18 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Bipolarity
RecruitingNCT07172516
This study is comparing Azetukalner, an experimental Kv7 potassium-channel opener, with placebo for people with bipolarity. Participants receive Azetukalner or placebo and complete study visits and assessments.
BipolarityDrugFrom 18 Years to 74 Years
- Countries
- United States
- Sponsor
- Xenon Pharmaceuticals Inc.
- Condition
- Bipolarity
RecruitingNCT07286175
This study is comparing Brenipatide with placebo for people with bipolarity. Participants receive Brenipatide or placebo and complete study visits and assessments.
BipolarityDrugFrom 18 Years to 75 Years
- Countries
- United States, Argentina, Brazil, China, India, Japan, Mexico
- Sponsor
- Eli Lilly and Company
- Condition
- Bipolarity
CompletedNCT05956340
This study is looking at care and outcomes for people with Manic Episode or Bipolarity I. Taking part may give some people access to Research interview, but direct benefit is not guaranteed.
BipolarityOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Mayo Clinic
- Condition
- Bipolarity
RecruitingNCT06696755
This study is looking at assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder for people with Bipolarity I or Bipolarity II. Participants receive Icalcaprant or placebo and complete study visits and assessments.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- AbbVie
- Condition
- Bipolarity
RecruitingNCT04777357
This study is comparing Cariprazine with placebo for people with Depression or Bipolarity I. Participants receive Cariprazine or placebo and complete study visits and assessments.
BipolarityDrugFrom 10 Years to 17 Years
- Countries
- United States, Russian Federation
- Sponsor
- AbbVie
- Condition
- Bipolarity
RecruitingNCT06929273
This study is looking at care and outcomes for people with bipolarity Type I With Mania. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States, Argentina, Australia, Bulgaria, China, Croatia, Denmark, France, Hungary, India, Israel, Italy, Japan, New Zealand, Poland, Romania, Slovakia, Spain, Sweden, Ukraine
- Sponsor
- Bristol-Myers Squibb
- Condition
- Bipolarity
RecruitingNCT07105111
This study is looking at care and outcomes for people with depression, psychosis, or bipolarity. Taking part may give some people access to Valbenazine, but direct benefit is not guaranteed.
SchizophreniaDrugOver 18 Years
- Countries
- United States
- Sponsor
- Neurocrine Biosciences
- Condition
- Schizophrenia
RecruitingNCT07140913
This study is looking at evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolarity type I for people with Mania or bipolarity. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States, Argentina, Bulgaria, China, Denmark, France, India, Israel, Italy, Japan, Poland, Romania, Ukraine
- Sponsor
- Bristol-Myers Squibb
- Condition
- Bipolarity
RecruitingNCT06951698
This study is looking at evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolarity type I for people with Bipolarity type I with mania or mania with mixed features. Participants are followed over time so researchers can learn from clinical and follow-up information.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States, Argentina, Australia, Bulgaria, Hungary, Japan, New Zealand, Poland
- Sponsor
- Bristol-Myers Squibb
- Condition
- Bipolarity
RecruitingNCT06951711
This observational study is following people with bipolarity Type I With Mania or mania with mixed features to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States, Croatia, India, Israel, Italy, Romania, Slovakia, Spain, Sweden, Ukraine
- Sponsor
- Bristol-Myers Squibb
- Condition
- Bipolarity
RecruitingNCT06656416
This study is looking at care and outcomes for people with bipolarity I or II With a Major Depressive Episode. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
BipolarityDrugFrom 18 Years to 70 Years
- Countries
- United States
- Sponsor
- Alto Neuroscience
- Condition
- Bipolarity
RecruitingNCT05849402
This study is looking at care and outcomes for people with Bipolarity II, Most Recent Episode Major Depressive, Current Depressive Episode, or Treatment Resistant Depression. Some participants may receive Sham aiTBS instead of the study treatment, and direct benefit is not guaranteed.
DepressionDeviceFrom 18 Years to 80 Years
- Countries
- United States
- Sponsor
- Stanford University
- Condition
- Depression
RecruitingNCT06706232
This study is looking at whether questionnaires and follow-up can help people with Bipolarity II, Depression in bipolarity, or Suicidality. Participants receive a study treatment and complete follow-up visits and assessments.
BipolarityDrugFrom 25 Years to 70 Years
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
- Condition
- Bipolarity
RecruitingNCT05491538
This study is looking at whether a digital support tool can help people with Schizophrenia, bipolarity, major depression, or Stress Disorder, Post-Traumatic. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.
DepressionBehavioralOver 18 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Depression
RecruitingNCT05838274
This study is looking at whether a digital support tool can help people with bipolarity, Alcohol Drinking, or Alcohol Use Disorder. Participants take part in a digital support tool and complete follow-up assessments.
BipolarityOtherFrom 21 Years to 26 Years
- Countries
- United States
- Sponsor
- University of Texas at Austin
- Condition
- Bipolarity
RecruitingNCT03522545
This study is comparing Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) with placebo for people with Treatment-resistant Depression in bipolarity. Participants receive Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) or placebo and complete study visits and assessments.
DepressionBiologicalFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
- Condition
- Depression
RecruitingNCT07288320
This study is looking at care and outcomes for people with Bipolarity I or Mania. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Neurocrine Biosciences
- Condition
- Bipolarity
Enrolling By InvitationNCT07217860
This study is testing Azetukalner, an experimental Kv7 potassium-channel opener, for people with bipolarity. Participants receive a study treatment and complete follow-up visits and assessments.
BipolarityOtherFrom 18 Years to 75 Years
- Countries
- United States
- Sponsor
- Xenon Pharmaceuticals Inc.
- Condition
- Bipolarity
Enrolling By InvitationNCT06823024
This observational study is following people with depression, anxiety, or bipolarity to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
DepressionOtherFrom 18 Years to 68 Years
- Countries
- United States
- Sponsor
- Psyrin Inc.
- Condition
- Depression
RecruitingNCT05457465
This observational study is following people with bipolarity to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
BipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Mclean Hospital
- Condition
- Bipolarity
CompletedNCT07116694
This study is looking at care and outcomes for people with psychosis or bipolarity. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.
BipolarityOtherFrom 18 Years to 75 Years
- Countries
- United States
- Sponsor
- BioXcel Therapeutics Inc
- Condition
- Bipolarity